INTRODUCTION: Propofol infusion syndrome (PRIS) is a rare, but potentially lethal adverse effect of a commonly used drug. We aimed to review and correlate experimental and clinical data about this syndrome. METHODS: We searched for all case reports published between 1990 and 2014 and for all experimental studies on PRIS pathophysiology. We analysed the relationship between signs of PRIS and the rate and duration of propofol infusion causing PRIS. By multivariate logistic regression we looked at the risk factors for mortality. RESULTS: Knowledge about PRIS keeps evolving. Compared to earlier case reports in the literature, recently published cases describe older patients developing PRIS at lower doses of propofol, in whom arrhythmia, hypertriglyceridaemia and fever are less frequently seen, with survival more likely. We found that propofol infusion rate and duration, the presence of traumatic brain injury and fever are factors independently associated with mortality in reported cases of PRIS (area under receiver operator curve = 0.85). Similar patterns of exposure to propofol (in terms of time and concentration) are reported in clinical cases and experimental models of PRIS. Cardiac failure and metabolic acidosis occur early in a dose-dependent manner, while arrhythmia, other electrocardiographic changes and rhabdomyolysis appear more frequently after prolonged propofol infusions, irrespective of dose. CONCLUSION: PRIS can develop with propofol infusion <4 mg/kg per hour and its diagnosis may be challenging as some of its typical features (hypertriglyceridaemia, fever, hepatomegaly, heart failure) are often (>95 %) missing and others (arrhythmia, electrocardiographic changes) occur late.

Adult Intensive Care Unit Nottingham University Hospitals NHS Trust Nottingham UK

Centre for Research on Diabetes Metabolism and Nutrition 3rd Faculty of Medicine Charles University Prague Prague Czech Republic

Department of Anaesthesiology and Intensive Care 3rd Faculty of Medicine Charles University Prague Prague Czech Republic

Laboratory for Metabolism and Bioenergetics 3rd Faculty of Medicine Charles University Prague Prague Czech Republic

Komentář v

Crit Care. 2016 Jul 04;20(1):197. doi: 10.1186/s13054-016-1364-8. PubMed

Zobrazit více v PubMed

Tiwari R. U.S. Anesthesia Drugs Market Worth $3 Billion + by 2018. http://www.prnewswire.com/news-releases/us-anesthesia-drugs-market-worth--3-billion-by-2018-285487841.html. Accessed 6 May 2015.

Global market study on propofol. http://www.aranca.com/downloads/case-studies/business-research/vertical-expertise/global-market-study-on-propofol-2-pharma-and-medical-devices-br-case-study.pdf. Accessed 6 May 2015.

Lonardo NW, Mone MC, Nirula R, Kimball EJ, Ludwig K, Zhou X, et al. Propofol is associated with favorable outcomes compared with benzodiazepines in ventilated intensive care unit patients. Am J Respir Crit Care Med. 2014;189(11):1383–94. doi: 10.1164/rccm.201312-2291OC. PubMed DOI

Fraser GL, Devlin JW, Worby CP, Alhazzani W, Barr J, Dasta JF, et al. Benzodiazepine versus nonbenzodiazepine-based sedation for mechanically ventilated, critically ill adults: a systematic review and meta-analysis of randomized trials. Crit Care Med. 2013;41(9 Suppl 1):S30–8. doi: 10.1097/CCM.0b013e3182a16898. PubMed DOI

Notis fra Bivirkningsnaenet. Propofol (Diprivan) bivirkninger. [Adverse effects of propofol (Diprivan)]. Ugeskr Laeger. 1990;152(16):1176. PubMed

Parke TJ, Stevens JE, Rice AS, Greenaway CL, Bray RJ, Smith PJ, et al. Metabolic acidosis and fatal myocardial failure after propofol infusion in children: five case reports. BMJ. 1992;305(6854):613–6. doi: 10.1136/bmj.305.6854.613. PubMed DOI PMC

Bodd E, Endresen L. Use of propofol for children. Tidsskr Nor Laegeforen. 1992;112:1636–7.

Kirkpatrick M, Cole G. Propofol infusion in children. BMJ. 1992;305(6863):1223. doi: 10.1136/bmj.305.6863.1223-a. PubMed DOI PMC

Barclay K, Williams AJ, Major E. Propofol infusion in children. BMJ. 1992;305(6859):953. doi: 10.1136/bmj.305.6859.953. PubMed DOI PMC

Bray RJ. Fatal myocardial failure associated with a propofol infusion in a child. Anaesthesia. 1995;50(1):94. doi: 10.1111/j.1365-2044.1995.tb04544.x. PubMed DOI

Strickland RA, Murray MJ. Fatal metabolic acidosis in a pediatric patient receiving an infusion of propofol in the intensive care unit: is there a relationship? Crit Care Med. 1995;23(2):405–9. doi: 10.1097/00003246-199502000-00029. PubMed DOI

Marinella MA. Lactic acidosis associated with propofol. Chest. 1996;109(1):292. doi: 10.1378/chest.109.1.292. PubMed DOI

Hanna JP, Ramundo ML. Rhabdomyolysis and hypoxia associated with prolonged propofol infusion in children. Neurology. 1998;50(1):301–3. doi: 10.1212/WNL.50.1.301. PubMed DOI

Perrier ND, Baerga-Varela Y, Murray MJ. Death related to propofol use in an adult patient. Crit Care Med. 2000;28(8):3071–4. doi: 10.1097/00003246-200008000-00066. PubMed DOI

Stelow EB, Johari VP, Smith SA, Crosson JT, Apple FS. Propofol-associated rhabdomyolysis with cardiac involvement in adults: chemical and anatomic findings. Clin Chem. 2000;46(4):577–81. PubMed

Cremer OL, Moons KG, Bouman EA, Kruijswijk JE, de Smet AM, Kalkman CJ. Long-term propofol infusion and cardiac failure in adult head-injured patients. Lancet. 2001;357(9250):117–8. doi: 10.1016/S0140-6736(00)03547-9. PubMed DOI

U.S. Food and Drug Administration MedWatch. 2001 safety alerts for drugs, biologics, medical devices, and dietary supplements. Diprivan (propofol). http://www.fda.gov/medwaTCH/SAFETY/2001/safety01.htm#diprivan%5D. Accessed 23 Dec 2014.

U.S. Food and Drug Administration. MedWatch. Detailed view: safety labeling changes approved by FDA Center for Drug Evaluation and Research (CDER)—February 2007. Diprivan (propofol) injectable emulsion for IV administration. http://www.fda.gov/Medwatch/SAFETY/2007/feb07.htm#Diprivan. Accessed 23 Dec 2014.

Ahlen K, Buckley CJ, Goodale DB, Pulsford AH. The ‘propofol infusion syndrome’: the facts, their interpretation and implications for patient care. Eur J Anaesthesiol. 2006;23(12):990–8. doi: 10.1017/S0265021506001281. PubMed DOI

Summary of Product Characteristics: PROPOFOL. https://www.medicines.org.uk/emc/medicine/2275#UNDESIRABLE_EFFECTS. Accessed 6 May 2015.

European Medicines Agency. European database of suspected drug reaction reports. https://bi.ema.europa.eu/analyticsSOAP/saw.dll?PortalPages. Accessed 6 May 2015.

Bray RJ. Propofol infusion syndrome in children. Pediatr Anesth. 1998;8(6):491–9. doi: 10.1046/j.1460-9592.1998.00282.x. PubMed DOI

Chukwuemeka A, Ko R, Ralph-Edwards A. Short-term low-dose propofol anaesthesia associated with severe metabolic acidosis. Anaesth Intensive Care. 2006;34(5):651–5. PubMed

Roberts RJ, Barletta JF, Fong JJ, Schumaker G, Kuper PJ, Papadopoulos S, et al. Incidence of propofol-related infusion syndrome in critically ill adults: a prospective, multicenter study. Crit Care. 2009;13(5):R169. doi: 10.1186/cc8145. PubMed DOI PMC

Richter S, Brugada P. Propofol-induced coved-type electrocardiogram during catheter ablation of paroxysmal atrial fibrillation. A case of Brugada syndrome? Herzschrittmacherther Elektrophysiol. 2012;23(1):56–8. doi: 10.1007/s00399-011-0156-8. PubMed DOI

Schroeppel TJ, Fabian TC, Clement LP, Fischer PE, Magnotti LJ, Sharpe JP, et al. Propofol infusion syndrome: a lethal condition in critically injured patients eliminated by a simple screening protocol. Injury. 2014;45(1):245–9. doi: 10.1016/j.injury.2013.05.004. PubMed DOI

Linko R, Laukkanen A, Koljonen V, Rapola J, Varpula T. Severe heart failure and rhabdomyolysis associated with propofol infusion in a burn patient. J Burn Care Res. 2014;35(5):e364–7. doi: 10.1097/BCR.0000000000000053. PubMed DOI

Rottenberg H. Uncoupling of oxidative phosphorylation in rat liver mitochondria by general anesthetics. Proc Natl Acad Sci U S A. 1983;80(11):3313–7. doi: 10.1073/pnas.80.11.3313. PubMed DOI PMC

Branca D, Roberti MS, Lorenzin P, Vincenti E, Scutari G. Influence of the anesthetic 2,6-diisopropylphenol on the oxidative phosphorylation of isolated rat liver mitochondria. Biochem Pharmacol. 1991;42(1):87–90. doi: 10.1016/0006-2952(91)90684-W. PubMed DOI

Branca D, Roberti MS, Vincenti E, Scutari G. Uncoupling effect of the general anesthetic 2,6-diisopropylphenol in isolated rat liver mitochondria. Arch Biochem Biophys. 1991;290(2):517–21. doi: 10.1016/0003-9861(91)90575-4. PubMed DOI

Rigoulet M, Devin A, Avéret N, Vandais B, Guérin B. Mechanisms of inhibition and uncoupling of respiration in isolated rat liver mitochondria by the general anesthetic 2,6-diisopropylphenol. Eur J Biochem. 1996;241(1):280–5. doi: 10.1111/j.1432-1033.1996.0280t.x. PubMed DOI

Branca D, Vincenti E, Scutari G. Influence of the anesthetic 2,6-diisopropylphenol (propofol) on isolated rat heart mitochondria. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol. 1995;110(1):41–5. doi: 10.1016/0742-8413(94)00078-O. PubMed DOI

Schenkman KA, Yan S. Propofol impairment of mitochondrial respiration in isolated perfused guinea pig hearts determined by reflectance spectroscopy. Crit Care Med. 2000;28(1):172–7. doi: 10.1097/00003246-200001000-00028. PubMed DOI

Mehta N, DeMunter C, Habibi P, Nadel S, Britto J. Short-term propofol infusions in children. Lancet. 1999;354(9181):866–7. doi: 10.1016/S0140-6736(05)75936-5. PubMed DOI

Cray SH, Robinson BH, Cox PN. Lactic acidemia and bradyarrhythmia in a child sedated with propofol. Crit Care Med. 1998;26:2087–92. doi: 10.1097/00003246-199812000-00046. PubMed DOI

Vanlander AV, Okun JG, de Jaeger A, Smet J, De Latter E, De Paepe B, et al. Possible pathogenic mechanism of propofol infusion syndrome involves coenzyme Q. Anesthesiology. 2015;122(2):343–52. doi: 10.1097/ALN.0000000000000484. PubMed DOI

Wolf A, Weir P, Segar P, Stone J, Shield J. Impaired fatty acid oxidation in propofol infusion syndrome. Lancet. 2001;357(9256):606–7. doi: 10.1016/S0140-6736(00)04064-2. PubMed DOI

Wolf AR, Potter F. Propofol infusion in children: when does an anesthetic tool become an intensive care liability? Paediatr Anaesth. 2004;14(6):435–8. doi: 10.1111/j.1460-9592.2004.01332.x. PubMed DOI

Withington DE, Decell MK, Al AT. A case of propofol toxicity: further evidence for a causal mechanism. Paediatr Anaesth. 2004;14(6):505–8. doi: 10.1111/j.1460-9592.2004.01299.x. PubMed DOI

Rinaldo P, Cowan TM, Matern D. Acylcarnitine profile analysis. http://www.nature.com/gim/journal/v10/n2/pdf/gim200822a.pdf. Accessed 6 May 2015. PubMed

Baumeister FA, Oberhoffer R, Liebhaber GM, Kunkel J, Eberhardt J, Holthausen H, et al. Fatal propofol infusion syndrome in association with ketogenic diet. Neuropediatrics. 2004;35(4):250–2. doi: 10.1055/s-2004-820992. PubMed DOI

Cree MG, Wolfe RR. Postburn trauma insulin resistance and fat metabolism. Am J Physiol Endocrinol Metab. 2008;294(1):E1–9. doi: 10.1152/ajpendo.00562.2007. PubMed DOI

Tong XX, Kang Y, Liu FZ, Zhang WS, Liu J. Effect of prolonged infusion of propofol on the liver mitochondria respiratory function in rabbits. Sichuan Da Xue Xue Bao Yi Xue Ban. 2010;41(6):1021–3. PubMed

Lee SK, Lee JO, Kim JH, Kim N, You GY, Moon JW, et al. Coenzyme Q10 increases the fatty acid oxidation through AMPK-mediated PPARα induction in 3 T3-L1 preadipocytes. Cell Signal. 2012;24(12):2329–36. doi: 10.1016/j.cellsig.2012.07.022. PubMed DOI

Jiang W, Yang ZB, Zhou QH, Huan X, Wang L. Lipid metabolism disturbances and AMPK activation in prolonged propofol-sedated rabbits under mechanical ventilation. Acta Pharmacol Sin. 2012;33(1):27–33. doi: 10.1038/aps.2011.155. PubMed DOI PMC

Lin MC, Chen CL, Yang TT, Choi PC, Hsing CH, Lin CF. Anesthetic propofol overdose causes endothelial cytotoxicity in vitro and endothelial barrier dysfunction in vivo. Toxicol Appl Pharmacol. 2012;265(2):253–62. doi: 10.1016/j.taap.2012.08.013. PubMed DOI

Kill C, Leonhardt A, Wulf H. Lacticacidosis after short-term infusion of propofol for anaesthesia in a child with osteogenesis imperfecta. Paediatr Anaesth. 2003;13(9):823–6. doi: 10.1046/j.1460-9592.2003.01114.x. PubMed DOI

Koch M, De Backer D, Vincent JL. Lactic acidosis: an early marker of propofol infusion syndrome? Intensive Care Med. 2004;30(3):522. doi: 10.1007/s00134-003-2130-3. PubMed DOI

Holzki J, Aring C, Gillor A. Death after re-exposure to propofol in a 3-year-old child: a case report. Paediatr Anaesth. 2004;14(3):265–70. doi: 10.1046/j.1460-9592.2003.01179.x. PubMed DOI

Romero PC, Morales RM, Donaire RL, Llanos VO, Cornejo RR, Gálvez AR, et al. Severe lactic acidosis caused by propofol infusion: report of one case. Rev Med Chil. 2008;136(1):88–92. doi: 10.4067/S0034-98872008000100011. PubMed DOI

Burow BK, Johnson ME, Packer DL. Metabolic acidosis associated with propofol in the absence of other causative factors. Anesthesiology. 2004;101(1):239–41. doi: 10.1097/00000542-200407000-00035. PubMed DOI

Haase R, Sauer H, Eichler G. Lactic acidosis following short-term propofol infusion may be an early warning of propofol infusion syndrome. J Neurosurg Anesthesiol. 2005;17(2):122–3. doi: 10.1097/01.ana.0000161267.63160.13. PubMed DOI

Westhout FD, Muhonen MG, Nwagwu CI. Early propofol infusion syndrome following cerebral angiographic embolization for giant aneurysm repair. Case report. J Neurosurg. 2007;106(2 Suppl):139–42. PubMed

Neubauer S. The failing heart—an engine out of fuel. N Engl J Med. 2007;356(11):1140–51. doi: 10.1056/NEJMra063052. PubMed DOI

Ypsilantis P, Politou M, Mikroulis D, Pitiakoudis M, Lambropoulou M, Tsigalou C, et al. Organ toxicity and mortality in propofol-sedated rabbits under prolonged mechanical ventilation. Anesth Analg. 2007;105(1):155–66. doi: 10.1213/01.ane.0000265544.44948.0b. PubMed DOI

Jouven X, Charles MA, Desnos M, Ducimetière P. Circulating nonesterified fatty acid level as a predictive risk factor for sudden death in the population. Circulation. 2001;104(7):756–61. doi: 10.1161/hc3201.094151. PubMed DOI

Stanley CA, Bennett MJ, Mayatepek E. Inborn metabolic diseases. Berlin: Springer Berlin Heidelberg; 2006. Disorders of mitochondrial fatty acid oxidation and related metabolic pathways; pp. 175–90.

Terrone G, Ruoppolo M, Brunetti-Pierri N, Cozzolino C, Scolamiero E, Parenti G, et al. Child neurology: recurrent rhabdomyolysis due to a fatty acid oxidation disorder. Neurology. 2014;82(1):e1–4. doi: 10.1212/01.wnl.0000438217.31437.72. PubMed DOI

Heyman MB, Storch S, Ament ME. The fat overload syndrome. Report of a case and literature review. Am J Dis Child. 1981;135(7):628–30. doi: 10.1001/archpedi.1981.02130310034012. PubMed DOI

Adolph M, Heller AR, Koch T, Koletzko B, Kreymann KG, Krohn K, et al. Lipid emulsions—Guidelines on Parenteral Nutrition, Chapter 6. Ger Med Sci. 2009;7:Doc22. PubMed PMC

Gura KM, Puder M. Rapid infusion of fish oil-based emulsion in infants does not appear to be associated with fat overload syndrome. Nutr Clin Pract. 2010;25(4):399–402. doi: 10.1177/0884533610373770. PubMed DOI

Fong JJ, Sylvia L, Ruthazer R, Schumaker G, Kcomt M, Devlin JW. Predictors of mortality in patients with suspected propofol infusion syndrome. Crit Care Med. 2008;36(8):2281–7. doi: 10.1097/CCM.0b013e318180c1eb. PubMed DOI

Commissioner OOT. MedWatch: The FDA Safety Information and Adverse Event Reporting Program. http://www.fda.gov/Safety/MedWatch/. Accessed 6 May 2015.

Effect of noradrenaline on propofol-induced mitochondrial dysfunction in human skeletal muscle cells

Kinetic characteristics of propofol-induced inhibition of electron-transfer chain and fatty acid oxidation in human and rodent skeletal and cardiac muscles